RT Journal Article
SR Electronic
T1 The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.24.21262385
DO 10.1101/2021.08.24.21262385
A1 Cabral-Marques, Otavio
A1 Halpert, Gilad
A1 Schimke, Lena F.
A1 Ostrinski, Yuri
A1 Zyskind, Israel
A1 Lattin, Miriam T.
A1 Tran, Florian
A1 Schreiber, Stefan
A1 Marques, Alexandre H.C.
A1 Filgueiras, Igor Salerno
A1 Plaça, Desirée Rodrigues
A1 Baiocchi, Gabriela Crispim
A1 Freire, Paula Paccielli
A1 Fonseca, Dennyson Leandro M.
A1 Humrich, Jens Y.
A1 Lange, Tanja
A1 Müller, Antje
A1 Giil, Lasse M.
A1 Graßhoff, Hanna
A1 Schumann, Anja
A1 Hackel, Alexander Maximilian
A1 Junker, Juliane
A1 Meyer, Carlotta
A1 Ochs, Hans D.
A1 Lavi, Yael Bublil
A1 Schulze-Forster, Kai
A1 Silvergerg, Jonathan I.
A1 Amital, Howard
A1 Zimmerman, Jason
A1 Heidecke, Harry
A1 Rosenberg, Avi Z
A1 Riemekasten, Gabriela
A1 Shoenfeld, Yehuda
YR 2021
UL http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262385.abstract
AB The coronavirus disease 2019 (COVID-19) can evolve to clinical manifestations resembling systemic autoimmune diseases, with the presence of autoantibodies that are still poorly characterized. To address this issue, we performed a cross-sectional study of 246 individuals to determine whether autoantibodies targeting G protein-coupled receptors (GPCRs) and renin-angiotensin system (RAS)-related molecules were associated with COVID-19-related clinical outcomes. Moderate and severe patients exhibited the highest autoantibody levels, relative to both healthy controls and patients with mild COVID-19 symptoms. Random Forest, a machine learning model, ranked anti-GPCR autoantibodies targeting downstream molecules in the RAS signaling pathway such as the angiotensin II type 1 and Mas receptor, and the chemokine receptor CXCR3 as the three strongest predictors of severe disease. Moreover, while the autoantibody network signatures were relatively conserved in patients with mild COVID-19 compared to healthy controls, they were disrupted in moderate and most perturbed in severe patients. Our data indicate that the relationship between autoantibodies targeting GPCRs and RAS-related molecules associates with the clinical severity of COVID-19, suggesting novel molecular pathways for therapeutic interventions.Competing Interest StatementThe authors declare that H.H. and K.S.F. are CellTrend managing directors and that GR is an advisor of the company CellTrend and earned an honorarium for her advice between 2011 and 2015. The other authors declare no competing interests.Funding StatementResearch Foundation (FAPESP grants 2018/18886-9, 2020/01688-0, and 2020/07069-0 to OCM; 2020/09146-1 to PPF) for financial support. Computational analysis was supported by FAPESP. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) founding the excellence cluster Precision Medicine in Inflammation, project TI4 and CD1, by the COVID fond of Schleswig-Holstein as well as the DFG project RI 1056 11-1/2.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All healthy controls and patients provided written consent to participate in the study, which was performed in accordance with the Declaration of Helsinki and approved by the IntegReview institutional review board. In addition, this study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA reporting summary for this article is available as a Supplementary Information file. The source data underlying the Main and Supplementary Figures are provided as a Source Data file. All R packages used in this manuscript are described in the Reporting Summary.